FDA recall D-0450-2022
Aurobindo Pharma USA Inc. · Class II · drug
Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
Reason for recall
Superpotent and Failed Tablet/Capsule Specifications
Distribution
Nationwide in the US
Key facts
- Status
- Terminated
- Initiation date
- 2021-12-29
- Report date
- 2022-02-02
- Termination date
- 2023-12-04
- Voluntary/Mandated
- Voluntary: Firm initiated
- Location
- East Windsor, NJ, United States
Primary source
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0450-2022